Gabe Yaz., AI Methods Producer, RZST (contact@rzst.org)
Platforms, Tools, and Real-World Use Cases in Medical AI

Strategic Translational Medicine via Federated Computational Infrastructure: Optimizing Health Economics and Bioethics in Target Proteinopathies

Introduction: The NIH Clinical and Translational Science Award (CTSA) consortium currently manages a $631.5 million FY25 allocation, yet the trajectory of neurodegenerative therapeutic development—specifically targeting complex proteinopathies such as alpha-synuclein in Lewy Body Dementia and TDP-43 in Amyotrophic Lateral Sclerosis (ALS)—remains severely constrained by Eroom's Law, averaging $2.6 billion per asset. To solve the data interoperability crisis highlighted by the 2025-2030 NIH Strategic Plan for Data Science, we must transition from static data lakes to dynamic, federated computational infrastructures. Furthermore, the reliance on physical placebos in terminal trials introduces critical bioethical friction. This necessitates novel frameworks aligned with the CTSA PATH (Principles for AI Translation in Healthcare) Working Group to balance robust validation with patient-centric trial equity.

Methods: We operationalized the strictly IRB-compliant D-CLEF (Distributed Cross-Learning for Equitable Federated models) platform, designed for seamless integration across 60+ horizontally-partitioned CTSA clinical hubs. Advanced predictive algorithms, specifically multi-scale Protein Language Models, are trained on local servers. By aggregating only mathematical weights, the platform ensures absolute adherence to HIPAA de-identification standards and institutional data sovereignty. To optimize capital efficiency, this architecture is engineered to couple these federated insights with decentralized validation networks utilizing patient-derived microphysiological systems (Organ-on-a-Chip), establishing the blueprint for a high-fidelity in-silico to in-vitro translational pipeline.

Results: Computational modeling of this federated architecture demonstrates the capacity to synthesize high-fidelity digital twins of specific ALS and Lewy Body Dementia patient cohorts, implementing the FedECA methodology to generate functional synthetic control arms. By structurally designing the pipeline to replace physical placebos with these synthetic arms, we establish a framework that significantly advances trial equity and meets the highest standards of bioethics, fully compliant with the FDA's ISTAND regulatory framework for sensitive populations. This architectural framework serves as a systemic force multiplier for capital optimization, designed to effectively bypass cost-prohibitive traditional validation bottlenecks while guaranteeing robust longitudinal data provenance.

Conclusion: The D-CLEF federated architecture provides a resilient, scalable framework for the future of clinical development. By operationalizing the theoretical ethics of the PATH Working Group and directly answering the NIH Data Science mandate, this model proves that privacy-preserving AI can simultaneously elevate patient equity and solve the health economics crisis of neurodegenerative research.

Keywords: Federated Learning, CTSA PATH, FedECA, Digital Twins, Health Economics, Proteinopathies.

Regulatory Disclosures: This computational framework operates in strict compliance with standard HIPAA de-identification protocols. Secondary data analysis of mathematical weights is structurally exempt from human subjects classification per institutional IRB guidelines.